A Biocompatible Hydrogen‐Bonded Organic Framework (HOF) as Sonosensitizer and Artificial Enzyme for In‐Depth Treatment of Alzheimer's Disease
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202402342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Junlin Ya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Key R&D Program of China, Natural Science Foundation of China, Jilin Innovation Project.
Themen: Demenz
Abstract (Originalsprache)
Current phototherapeutic approaches for Alzheimer's disease (AD) exhibit restricted clinical outcomes due to the limited physical penetration and comprised brain microenvironment of noninvasive nanomedicine. Herein, a hydrogen‐bonded organic framework (HOF) based sonosensitizer is designed and synthesized. Mn‐TCPP, a planar molecule where Mn 2+ ion is chelated in the core with a large p‐conjugated system and 4 carboxylate acid groups, has been successfully used as building blocks to construct an ultrasound‐sensitive HOF (USI‐MHOF), which can go deep in the brain of AD animal models. The both in vitro and in vivo studies indicate that USI‐MHOF can generate singlet oxygen ( 1 O 2 ) and oxidize β‐amyloid (Aβ) to inhibit aggregation, consequently attenuating Aβ neurotoxicity. More intriguingly, USI‐MHOF exhibits catalase (CAT)‐ and superoxide dismutase (SOD)‐like activities, mitigating neuron oxidative stress and reprograming the brain microenvironment. For better crossing the blood‐brain barrier (BBB), the peptide KLVFFAED (KD8) has been covalently grafted to USI‐MHOF for improving BBB permeability and Aβ selectivity. Further, in vivo experiments demonstrate a significant reduction of the craniocerebral Aβ plaques and improvement of the cognition deficits in triple‐transgenic AD (3×Tg‐AD) mice models following deep‐penetration ultrasound treatment. The work provides the first example of an ultrasound‐responsive biocompatible HOF as non‐invasive nanomedicine for in‐depth treatment of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, P. R. China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, Anhui, 230029, P. R. China.
ORCID-Profile: Xiaogang Qu
Förderung
- National Key R&D Program of China
- Natural Science Foundation of China
- Jilin Innovation Project
- Jilin Province Science and Technology Development Plan Project
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Ya, J., Zhang, H., Qin, G., Huang, C., Zhao, C., Ren, J., & Qu, X. (2024). A Biocompatible Hydrogen‐Bonded Organic Framework (HOF) as Sonosensitizer and Artificial Enzyme for In‐Depth Treatment of Alzheimer's Disease. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402342
Vancouver
Ya J, Zhang H, Qin G, Huang C, Zhao C, Ren J, et al. A Biocompatible Hydrogen‐Bonded Organic Framework (HOF) as Sonosensitizer and Artificial Enzyme for In‐Depth Treatment of Alzheimer's Disease. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202402342
BibTeX
@article{Ya2024,
author = {Ya, Junlin and Zhang, Haochen and Qin, Geng and Huang, Congcong and Zhao, Chuanqi and Ren, Jinsong and Qu, Xiaogang},
title = {A Biocompatible Hydrogen‐Bonded Organic Framework (HOF) as Sonosensitizer and Artificial Enzyme for In‐Depth Treatment of Alzheimer's Disease},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202402342}
}
EUVIMED